scientists discover a potential treatment to prevent diabetes
Granada scientists have discovered a potential treatment to prevent diabetes and obesity, whose experimental results demonstrate an improvement in insulin sensitivity and glucose absorption and an increase in the expression of important genes related to fat metabolism.
This is an international project in which researchers from Vitagenas have participated, a company promoted by the University of Granada (UGR) and located in the Technology Park of Health Sciences (PTS), the Granada academic institution reported in a statement.
VitAGenes has collaborated in this project through its technical director, Dr. José Luis Mesa, who has been one of the main authors of the study along with outstanding scientists from the University of Melburne and Baker Heart Research Institute (Australia), whose mainResults have been published in the international scientific journal Journal of Endocrinology.
As the main finding, the paradigm shift of a molecule called Interleuquina-6 stands out in the prevention of obesity and diabetes.
So far, scientific evidence suggested that Interleuquina-6, being high in obese and diabetics, could be harmful to obesity and diabetes, although this study shows the opposite.
'No study had tried to inject directly-6 to analyze whether this molecule was really harmful or, on the contrary, it could help prevent obesity and diabetes,' said José Luis Mesa.
The researchers' hypothesis was that the intent-6 was naturally elevated in obese and diabetics precisely to combat such diseases.
To demonstrate it, they injected interleuquina-6 human recombinant daily for two weeks and analyzed their behavior and their effects on metabolism.
Mark Febbraio, scientific director at the Baker Heart Research Institute and a member of the Vitagen Advisory Scientific Committee, has indicated that 'the results were surprising: the exogenous administration of Interleuquina-6 improved the sensitivity to insulin and glucose absorption, something essentialin diabetics'.
In addition, as explained by Mesa, 'the Interleuquina-6 also increased the expression of important genes related to fat metabolism, such as PPAR and UCP2, which suggests that the interleuquina-6 could be involved in the metabolic control of body weight'.
However, Vitagen has warned that this study is preliminary, and carried out in animal models, so new studies in humans are necessary to establish definitive conclusions, although it has nuanced that 'everything seems to indicate that the application in humans would be possibleIn the medium term, which could substantially improve the state of people with diabetes and obesity '.